SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-045601
Filing Date
2022-08-09
Accepted
2022-08-09 08:15:43
Documents
14
Period of Report
2022-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea163937-8k_protara.htm   iXBRL 8-K 27388
2 PRESS RELEASE DATED AUGUST 9, 2022, ISSUED BY THE REGISTRANT ea163937ex99-1_protaratherap.htm EX-99.1 72744
6 GRAPHIC ex99-1_001.jpg GRAPHIC 7913
  Complete submission text file 0001213900-22-045601.txt   295025

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tara-20220809.xsd EX-101.SCH 2962
4 XBRL LABEL FILE tara-20220809_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE tara-20220809_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT ea163937-8k_protara_htm.xml XML 3613
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 221146512
SIC: 2836 Biological Products, (No Diagnostic Substances)